维普中文期刊产品整合服务
80篇 您的检索式:作者名="CINDY L"
    题名 作者 年代 出处 被引量
1FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts显示文摘AIM: To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHODS: All consecutive patients with histologically confirmed, metastatic PAC and World Health Organiza-tion performance status (PS) ≤ 2 received FOLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FOLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FOLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FOLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FOLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FOLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median OS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated with poor TTP [hazard ratio (HR): 16.036, P < 0.0001] and OS (HR: 4.003, P = 0.004). CONCLUSION: The FOLFIRI regimen had an acceptable toxicity and an interesting efficacy in our study, limited to patients in good condition (PS 0-1).Cindy Neuzillet Olivia Hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet Pascal Hammel 2012World Journal of Gastroenterology2012,18,33:3
2Short bowel syndrome and crohn’s disease显示文摘Jon S Thompson Kishore R Iyer John K DiBaise Renee L Young Cindy R Brown Alan N Langnas 2003Journal of Gastrointestinal Surgery2003,,8:1
3Depression anxiety and quality of life in patients with epithelial ovarian cancer 显示文摘Diane Bodurka Bevers Karen Basen Engquist Cindy L Carmack 2000Gynecologic oncology2000,78,3:1
4Comparison of Total Hip Arthroplasty performed with and without cement:a randomized trial显示文摘Andreas L Robert B Cecil Ik David F Peter T Cindy W 2002J Bone Joint Surg Am2002,84,10:1
5MBR application will gain in popularity显示文摘Cindy W L James L B 2001H2O MBR Special2001,12,6:1
6Endophytic bacteria and their potential applications显示文摘Cindy L Jaco V Fiona P 2002Crit Rev Plant Sci2002,21,:1
7Characterization of polyploid wheat genomic diversity using a high-density 90 000 single nucleotide polymorphism array 显示文摘Wang SC Debbie W Kerrie F Alexandra A Shiaoman C Bevan EH Marco M Silvio S Sara GM Luigi C Anna MM Alex W Stuart S Gary B Ralf W Joerg P International Wheat Genome Sequencing Consortium Morten L Diane M Rudi A Rudy D Gina BG Abraham K Alina RA Catherine F Jerome S Michele M Curtis P Luo MC Jan DMM Jorge D Martin G Roberto T Cindy L Ivan M Colin C Keith JE Matthew H Eduard A 2014Plant Biotechnol J2014,12,:1
8Oral car in the adult intensive care unit显示文摘Julie A Fitch Cindy L Munro Connie A Glass 1999Am J Crit Care1999,8,5:1
9Benefits and risks of abeiximab use in primary angiopalasty for acute myocaniial infarction显示文摘James E David E Cindy L 2003Circulation2003,108,11:1
10Chlorhexidine,tooth-brushing* and preventing ventilator-associated pneumonia incritically ill adults显示文摘Cindy L Mary Jo Deborah J 2009Am J Crit Care2009,18,5:1
11Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infaretion: quantitative review of randomised trials 显示文摘Ellen C Keeley Judith A Boura Cindy L Grines 2006Laneet2006,367,9510:1
12Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification显示文摘Beth A Bartholomew Kishore J Harjai Srinivas Dukkipati Judith A Boura Michael W Yerkey Susan Glazier Cindy L Grines William W O’Neill 2004The American Journal of Cardiology2004,,12:1
13Development and psychometric testing of the Breastfeeding Self-Efficany Scale显示文摘Cindy L D Sandra F 1999Res Nurs Health1999,22,5:1
14Oral health and care in the intensive care unit:state of the science显示文摘Cindy L Munro Mary Jo Grap Ruth Kleinpell 2004Am J Crit Care2004,13,1:1
15Oral health and care in the intensive care unit: state of scienee显示文摘Cindy L Munro Mary Jo Grap Ruth Kleinpell 2004Am J Crit Care2004,13,1:1
16Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro显示文摘Cindy S Filip L Bea P 2008BMC Cancer2008,8,:1
17Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction显示文摘James E David E Cindy L et at 2003Circulation2003,108,11:1
18Relative bioavailability of β-carotene from supplement sources显示文摘Cindy J Fuller Dale N Butterfoss Mark L Failla 2001Nutrition Research2001,21,:1
19Comparative study of the radiosen-sitising and cell cycle effects of vinflunine and vinorelbine,in vitro显示文摘Cindy S Filip L Bea P 2008BMC Cancer2008,8,:1
20Is This Review Believable? A Study of Factors Affecting the Credibility of Online Consumer Reviews from an ELM Perspective显示文摘Cheung M Y Cindy M Y Sia C L 2012Journal of the Association for Information Systems2012,13,8:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费